Clinical StudiesBacteraemia due to AmpC β-lactamase-producing Escherichia coli in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes
Introduction
The gram-negative bacillus Escherichia coli is one of the most common causes of bacteraemia in patients with cancer (Ha et al., 2011). Recently, acquired AmpC β-lactamase-producing Escherichia coli (AmpC-EC) has emerged as an important pathogen, which is markedly associated with community-onset and hospital-acquired infections worldwide (Lee et al., 2015, Matsumura et al., 2013). Especially plasmid-mediated AmpC-EC has frequently arisen through the transfer of the inducible AmpC β-lactamase gene from chromosome to plasmids. This often results in hydrolyzing all β-lactam antibiotics except cefepime and carbapenems, and conferring resistance to cephalothin, cefazolin, cefoxitin, most penicillins, and β-lactam inhibitor combinations (broad multidrug resistance), which has become a major problem in health care settings (Harris, 2015). Cancer patients with immunodeficiency are especially particularly vulnerable to infection by AmpC-producing pathogens, due to the fact that most cancer patients undergo treatments involving invasive surgery, chemotherapy, radiotherapy, immunosuppressive agents, or anticancer drugs during their hospital stay. To the best of our knowledge, information on the characteristics of AmpC-EC, particularly clinic associated data is fairly limited (Lee et al., 2015, Pascual et al., 2015). Therefore, the aim of this study was to assess risk factors, antibiotic therapy, and outcomes of AmpC-EC bacteraemia in hospitalized cancer patients.
Section snippets
Setting and study design
This retrospective study was conducted at the Tianjin Medical University Cancer Institute and Hospital, a 2400 bed tertiary care cancer center in China (http://www.tmucih.org/). The electronic medical record database was twice-reviewed by Dr. Ding Li and Dr. Shan Zheng to accurately identify patients who were diagnosed with cancer and who also had an episode of E. coli bacteraemia between September 2012 and December 2015. Only the first infection episode of each patient was included in the
Clinical characteristics and risk factors for AmpC-EC in cancer patients
During the study period, 325 cases of Escherichia coli bacteraemia in hospitalized cancer patients were identified, 77 patients with ESBL-producing isolates were excluded and 248 were enrolled. The bacteraemia of 197 patients was caused by non-AmpC-EC and 51 were caused by AmpC-EC. AmpC-EC was mainly identified from pancreatic cancer (21.6%), colorectal cancer (15.7%), gastric carcinoma (13.7%), hepatic carcinoma (11.7%), and gynecological cancer patients (13.7%). The mean age of the study
Discussion
The prevalence of AmpC-EC isolates that gain resistance to broad-spectrum cephalosporins has been increasing in recent years (Jacoby, 2009, Liu and Liu, 2016). A limited selection of antimicrobial agents can be used to treat infections caused by these organisms. The present study showed that 51 (20.5%) AmpC-EC infections were isolated in our area (Fig. S2), which was a higher prevalence than Asian and Euro-American countries (Adler et al., 2008, Alvarez et al., 2004, Coudron et al., 2000b, Ding
Funding
This work was supported by the National Natural Science Found of China (No.30700829, No.81373318] the Specialized Research Fund for Doctoral Program of Higher Education of China (No.20130031120037), and the Natural Science Found of Tianjin (No. 16JCYBJC23900). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests
No conflicts of interest.
Ethical Approval
Not required.
Acknowledgement
Thanks to Dr. Edward C. Mignot, Shandong University, for linguistic advice.
References (24)
- et al.
Risk factors and treatment outcomes of bloodstream infection caused by extended-spectrum cephalosporin-resistant Enterobacter species in adults with cancer
Diagn Microbiol Infect Dis
(2014) - et al.
Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae
J Microbiol Immunol Infect
(2015) - et al.
High Prevalence of AmpC β-Lactamases in Clinical Isolates of Escherichia coli in Ilam, Iran
Osong Public Health Res Perspect
(2015) - et al.
Molecular and clinical characterization of plasmid-mediated AmpC β-lactamase-producing Escherichia coli bacteraemia: a comparison with extended-spectrum β-lactamase-producing and non-resistant E. coli bacteraemia
Clin Microbiol Infect
(2013) - et al.
Infections due to Escherichia coli producing extended-spectrum β-lactamase among hospitalised patients: factors influencing mortality
J Hosp Infect
(2008) - et al.
Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with haematological malignancies
J Infect
(2009) - et al.
Plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes: prevalence at a Swiss university hospital and occurrence of the different molecular types in Switzerland
J Antimicrob Chemother
(2008) - et al.
Epidemiology of conjugative plasmid-mediated AmpC betalactamases in the United States
Antimicrob Agents Chemother
(2004) - et al.
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992
Chest
(2009) Performance standards for antimicrobial susceptibility testing: twenty first informational supplement M100-S20
(2010)
Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebacteraemiaella pneumoniae, and Proteus mirabilis isolates at a veterans medical center
J Clin Microbiol
Occurrence and detection of AmpC beta-Lactamases among Escherichia coli, Klebacteraemiaella pneumoniae, and Proteus mirabilis isolates at a veterans medical center
Clin Microbiol
Cited by (10)
The association between methylmalonic acid, a biomarker of mitochondria dysfunction, and phenotypic age acceleration: A population-based study
2024, Archives of Gerontology and GeriatricsRisk factors and diagnostic markers for Escherichia coli bloodstream infection in older patients
2021, Archives of Gerontology and GeriatricsCitation Excerpt :Another risk factor identified was urinary system infection. This was in agreement with a retrospective study that demonstrated a correlation between urinary tract infection and the risk of BSI (Abernethy et al., 2017; Zhang et al., 2017). Additionally, it is known that E. coli is a common cause of urinary tract infection, which can progress to BSI.
Clinical outcomes of antimicrobial resistance in cancer patients: a systematic review of multivariable models
2023, BMC Infectious DiseasesTargeted literature review of the burden of extraintestinal pathogenic Escherichia Coli among elderly patients in Asia Pacific regions
2023, Journal of Medical Economics